Published in Mediators Inflamm on January 01, 1995
Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity. J Exp Med (1982) 5.33
Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science (1989) 3.90
G proteins. Trends Biochem Sci (1992) 3.79
Demonstration of a soluble mediator that induces exudates rich in Ia-positive macrophages. J Exp Med (1980) 2.38
Signal integration at the level of protein kinases, protein phosphatases and their substrates. Trends Biochem Sci (1992) 2.00
Crosstalk among multiple signal-activated phospholipases. Trends Biochem Sci (1992) 1.36
Interferon-gamma-induced astrocyte class II major histocompatibility complex gene expression is associated with both protein kinase C activation and Na+ entry. J Biol Chem (1991) 1.03
Interferon-induced class II expression at the spongiotrophoblastic zone of the murine placenta is linked to fetal rejection and developmental abnormalities. Acta Physiol Scand (1994) 0.98
Regulation of HLA class II antigen expression: intracellular signaling molecules responsible for the regulation by IFN-gamma and cross-linking of Fc receptors in HL-60 cells. J Immunol (1987) 0.95
Transduction of the IFN-gamma signal for HLA-DR expression in the promonocytic line THP-1 involves a late-acting PKC activity. Cell Immunol (1991) 0.94
Type II interferon may be a potential hazardous therapeutic agent during pregnancy. Br J Haematol (1992) 0.91
Investigation of intracellular signals generated by gamma-interferon and IL-4 leading to the induction of class II antigen expression. Mediators Inflamm (1993) 0.90
Mevalonate availability and cardiovascular functions. Proc Natl Acad Sci U S A (1993) 0.86
Prostaglandins: their disappearance from and release into the circulation. Nature (1967) 8.66
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
Prostaglandins, aspirin-like drugs and analgesia. Nat New Biol (1972) 4.91
The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol (1992) 3.21
Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20
A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci U S A (2005) 2.53
The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmacol Chemother (1967) 2.44
Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect Immun (1994) 2.35
Central and peripheral antialgesic action of aspirin-like drugs. Eur J Pharmacol (1978) 2.18
Involvement of resident macrophages and mast cells in the writhing nociceptive response induced by zymosan and acetic acid in mice. Eur J Pharmacol (2000) 2.16
Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol (1973) 2.07
Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect Immun (1995) 1.94
Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry (1970) 1.86
Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur J Immunol (1994) 1.82
Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity. Circulation (2000) 1.82
Proceedings: Prostaglandin generation maintains the smooth muscle tone of the rabbit isolated jejunum. Br J Pharmacol (1972) 1.80
The detection and estimation of bradykinin in the circulating blood. Br J Pharmacol Chemother (1967) 1.80
Feedback inhibition of nitric oxide synthase activity by nitric oxide. Br J Pharmacol (1993) 1.79
The hyperalgesic effects of prostacyclin and prostaglandin E2. Prostaglandins (1978) 1.74
Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol (2005) 1.74
Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol (1991) 1.71
Recombinant interleukin-1 and tumor necrosis factor induce neutrophil migration "in vivo" by indirect mechanisms. Agents Actions (1990) 1.71
Participation of the sympathetic system in acetic acid-induced writhing in mice. Braz J Med Biol Res (1988) 1.66
Chemokines in oral inflammatory diseases: apical periodontitis and periodontal disease. J Dent Res (2007) 1.65
Modulation of mucosal immunity in a murine model of food-induced intestinal inflammation. Clin Exp Allergy (2007) 1.65
II - Prostaglandin hyperalgesia: the peripheral analgesic activity of morphine, enkephalins and opioid antagonists. Prostaglandins (1979) 1.63
An electronic pressure-meter nociception paw test for mice. Braz J Med Biol Res (2004) 1.56
IL-8 causes in vivo neutrophil migration by a cell-dependent mechanism. Immunology (1991) 1.54
A peripheral sympathetic component in inflammatory hyperalgesia. Eur J Pharmacol (1987) 1.53
I - Prostaglandin hyperalgesia, a cAMP/Ca2+ dependent process. Prostaglandins (1979) 1.52
Some effects of inhibiting endogenous prostaglandin formation on the responses of the cat spleen. Br J Pharmacol (1973) 1.47
Blockade by antimacrophage serum of the migration of PMN neutrophils into the inflamed peritoneal cavity. Agents Actions (1985) 1.45
Mouse paw edema. A new model for inflammation? Braz J Med Biol Res (1987) 1.42
Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors. Oral Microbiol Immunol (2006) 1.40
An electronic pressure-meter nociception paw test for rats. Braz J Med Biol Res (2004) 1.39
The effects of antiinflammatory drugs on the production of prostaglandins in vivo. Adv Prostaglandin Thromboxane Res (1976) 1.36
Inhibition of prostaglandin biosynthesis as the mechanism of analgesia of aspirin-like drugs in the dog knee joint. Eur J Pharmacol (1975) 1.34
The dual role of p55 tumour necrosis factor-alpha receptor in Actinobacillus actinomycetemcomitans-induced experimental periodontitis: host protection and tissue destruction. Clin Exp Immunol (2007) 1.32
Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Eur J Pharmacol (1990) 1.32
Role of nitric oxide in the failure of neutrophil migration in sepsis. J Infect Dis (2000) 1.30
The major role of peripheral release of histamine and 5-hydroxytryptamine in formalin-induced nociception. Neuroscience (2001) 1.30
A laminar flow superfusion technique with much increased sensitivity for the detection of smooth muscle-stimulating substances. Eur J Pharmacol (1976) 1.29
Prostaglandin production by rabbit isolated jejunum and its relationship to the inherent tone of the preparation. Br J Pharmacol (1976) 1.29
Commensal microbiota is fundamental for the development of inflammatory pain. Proc Natl Acad Sci U S A (2008) 1.28
Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature (1970) 1.27
Half-lives of peptides and amines in the circulation. Nature (1967) 1.27
An excitatory nociceptive cardiac reflex elicited by bradykinin and potentiated by prostaglandins and myocardial ischaemia. Cardiovasc Res (1976) 1.24
A crucial role for TNF-alpha in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5. Br J Pharmacol (2009) 1.23
Rat knee-joint carrageenin incapacitation test: an objective screen for central and peripheral analgesics. Pain (1992) 1.22
Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia. Br J Pharmacol (1999) 1.22
Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. Eur J Pharmacol (2000) 1.21
Peripheral analgesic action of clonidine: mediation by release of endogenous enkephalin-like substances. Eur J Pharmacol (1988) 1.20
Action of bradykinin potentiating factor (BPF) and dimercaprol (BAL) on the responses to bradykinin of isolated preparations of rat intestines. Br J Pharmacol (1971) 1.20
Growth phase-dependent subcellular localization of nitric oxide synthase in maize cells. FEBS Lett (1999) 1.19
Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br J Pharmacol (1995) 1.17
Gamma interferon modulates CD95 (Fas) and CD95 ligand (Fas-L) expression and nitric oxide-induced apoptosis during the acute phase of Trypanosoma cruzi infection: a possible role in immune response control. Infect Immun (1999) 1.17
Further experiments to establish that the analgesic action of aspirin-like drugs depends on the inhibition of prostaglandin biosynthesis. Br J Pharmacol (1973) 1.16
Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Br J Pharmacol (1997) 1.15
Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br J Pharmacol (2000) 1.14
Neutrophil migration induced by inflammatory stimuli is reduced by macrophage depletion. Agents Actions (1988) 1.13
Proceedings: Potentiation by prostaglandins of the nociceptive activity of bradykinin in the dog knee joint. Br J Pharmacol (1974) 1.12
Sequential induction of nitric oxide synthase by Corynebacterium parvum in different organs of the mouse. Br J Pharmacol (1995) 1.12
The release of a neutrophil chemotactic factor from peritoneal macrophages by endotoxin: inhibition by glucocorticoids. Eur J Pharmacol (1986) 1.12
Tumour necrosis factor-alpha and leukotriene B(4) mediate the neutrophil migration in immune inflammation. Br J Pharmacol (2001) 1.12
Analgesia by direct antagonism of nociceptor sensitization involves the arginine-nitric oxide-cGMP pathway. Eur J Pharmacol (1992) 1.11
Bradykinin and functional vasodilatation in the salivary gland. Br J Pharmacol (1976) 1.10
Heme oxygenase/carbon monoxide-biliverdin pathway down regulates neutrophil rolling, adhesion and migration in acute inflammation. Br J Pharmacol (2006) 1.10
Mode of analgesic action of dipyrone: direct antagonism of inflammatory hyperalgesia. Eur J Pharmacol (1985) 1.09
Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization. Eur J Pharmacol (1994) 1.06
Analgesic effect of thalidomide on inflammatory pain. Eur J Pharmacol (2000) 1.06
Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4. Br J Pharmacol (1999) 1.06
The continuous bioassay of the release and disappearance of histamine in the circulation. Br J Pharmacol (1973) 1.05
Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect Immun (2006) 1.05
Blockade of the inflammatory effects of platelet-activating factor by cyclo-oxygenase inhibitors. Braz J Med Biol Res (1981) 1.04
Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol (2000) 1.04
Bradykinin B1 and B2 receptors, tumour necrosis factor alpha and inflammatory hyperalgesia. Br J Pharmacol (1999) 1.02
Are platelets important in inflammation? Agents Actions (1975) 1.01
A role for the MAPK/ERK pathway in oligodendroglial differentiation in vitro: stage specific effects on cell branching. Int J Dev Neurosci (2009) 1.01
A new method for measuring variations of rat paw volume. J Pharm Pharmacol (1979) 1.00
iNOS-derived nitric oxide modulates infection-stimulated bone loss. J Dent Res (2008) 1.00
Involvement of NO in the failure of neutrophil migration in sepsis induced by Staphylococcus aureus. Br J Pharmacol (2002) 0.99